FDA approves use of Evusheld

FDA approves use of Evusheld

The Food and Drug Administration has approved the use of Evusheld, a combination of long-acting antibodies, for prevention of Covid-19, FDA director Paisal Dankhum said on Wednesday.

Evusheld combines monoclonal antibodies for the prevention, not treatment, of Covid-19. It is not intended to be a substitute for coronavirus vaccines.

It was developed by AstraZeneca and approved by the FDA for emergency use on June 27. It has also been authorised for emergency use by the US Food and Drug Administration and the European Union.

Evusheld is a combination of two active substances, tixagevimab co-packaged with cilgavimab, and works on the principle of "passive immunisation".

It is administered as two injections, with protection lasting for at least six months.

It can be used in adults and children from 12 years of age up weighing at least 40 kilogrammes.

Dr Paisal said people who need to use this medicine should provide doctors with information such as their history of allergies, treatment for coronary artery disease, pregnancy and vaccination history.

Do you like the content of this article?
COMMENT (6)
TRENDING

ThaiBev puts off brewery IPO again

SINGAPORE: Thai Beverage Plc has deferred the initial public offering of its brewery unit in Singapore once again, citing “prolonged challenging market conditions” for its decision.

21:32

Prawit's birthday cake leaves a bad taste

Palang Pracharath members abruptly ordered a new birthday cake for party leader Prawit Wongsuwon on Thursday after the original drew scathing reviews for bad taste on social media.

20:54

Looking for answers

The daughter of a man whose dead body was found in his car almost 12 hours after a crash in Chon Buri has filed a complaint against police and rescuers.

20:17